Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Significance: Although tuberculosis is a curable disease, its etiological agent, Mycobacterium tuberculosis ( Mtb ), remains a major human pathogen. Control of Mtb is hindered by multidrug-resistant strains, which can be currently treated with second-line agents that include fluoroquinolones such as moxifloxacin. Unfortunately, fluoroquinolone resistance is increasing, making improvements to quinolone efficacy clinically important. Fluoroquinolones act by forming complexes that poison Mtb . To our knowledge, this study describes the first X-ray crystal structures of the Mtb gyrase cleavage core complexed with DNA and five fluoroquinolones. These comparative structures inform efforts to design new quinolone-class agents and establish that the low intrinsic susceptibility of Mtb to clinically used fluoroquinolones is due to a paucity of specific gyrase–drug interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis.”
MethodCoot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Clustal W and Clustal X version 2.0
Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,358
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282 · cited 1×
“Fluoroquinolones prevent the resealing of the ds breaks that normally follows DNA strand passage (25), generating persistent, covalent enzyme–DNA adducts called cleaved complexes.”
BackgroundSelf-citationOptimal description of a protein structure in terms of multiple groups undergoing TLS motion
Painter, J., & Merritt, E. A. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906005270 · Cited by 1,240
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042 · cited 1×
“For example, gatifloxacin can elicit side effects such as hypo/hyperglycemia (12), whereas moxifloxacin has potential cardiovascular risks (13).”
BackgroundGandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC
Li, M. Z., & Elledge, S. J. (2007) · Nature Methods · doi:10.1038/nmeth1010 · Cited by 953
The Process of Structure-Based Drug Design
Anderson, A. C. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.09.002 · Cited by 939 · cited 1×
“Stacking energetics can also be difficult to modulate through structure-based drug design approaches (52, 53), which struggle with the accurate accounting of factors such as flexibility or the entropy of drug binding (54).”
BackgroundType IIA topoisomerase inhibition by a new class of antibacterial agents
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860 · cited 4×
“aureus gyrase (30) (PDB ID code 2XCT, yellow).”
BackgroundMethodInfluentialQuinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M., & Nakamura, S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.8.1647 · Cited by 777
TLSMD web server for the generation of multi-group TLS models
Painter, J., & Merritt, E. A. (2006) · Journal of Applied Crystallography · doi:10.1107/s0021889805038987 · Cited by 756
Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli
Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., ZiaZarifi, A. H., & Hoffner, S. E. (2009) · Chest · doi:10.1378/chest.08-2427 · Cited by 607
Quinolone-Mediated Bacterial Death
Drlica, K., Malik, M., Kerns, R. J., & Zhao, X. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-06 · Cited by 570 · cited 1×
“Cleaved-complex formation, which is reversible, blocks bacterial growth; at elevated fluoroquinolone concentrations, release of DNA breaks from the complexes leads to chromosome fragmentation and cell death (26).”
BackgroundSelf-citationFluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403 · cited 4×
“Surprisingly, we could identify no specific interactions between the different fluoroquinolones and gyrase that might account for established differences in their antibacterial activities in vivo (2, 7, 10).”
BackgroundInfluentialModel bias in macromolecular crystal structures
Hodel, A., Kim, S. H., & Brünger, A. T. (1992) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767392006044 · Cited by 401
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376 · cited 1×
“A challenge to such efforts will be to avoid the sole use of MIC as a means to score compound efficacy, and instead focus on cell killing, which mitigates resistance (62).”
BackgroundSelf-citationOutpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367 · cited 3×
“Antimicrob Agents Chemother 54(12):5214–5221.”
BackgroundAncestral antibiotic resistance in Mycobacterium tuberculosis
Morris, R. P., Nguyen, L., Gatfield, J., Visconti, K., Nguyen, K., Schnappinger, D., Ehrt, S., Liu, Y., Heifets, L., Pieters, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505446102 · Cited by 333 · cited 2×
“Mtb is well known to have a low susceptibility to fluoroquinolones (34, 35).”
BackgroundStructural basis for gate-DNA recognition and bending by type IIA topoisomerases
Dong, K. C., & Berger, J. M. (2007) · Nature · doi:10.1038/nature06396 · Cited by 316 · cited 1×
“2 C and D); this region has been seen in different conformational states in other type IIA topoisomerase structures (41, 42).”
BackgroundSelf-citationStructural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1892 · Cited by 310 · cited 7×
“baumannii topo IV, PDB ID code 2XKK) (29).”
BackgroundMethodInfluentialStructural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases
Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X.-S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., & Sanderson, M. R. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1604 · Cited by 304
Conde, M. B., Efron, A., Loredo, C., De Souza, G. R. M., Graça, N. P., Cezar, M. C., Ram, M., Chaudhary, M. A., Bishai, W. R., Kritski, A. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60333-0 · Cited by 289 · cited 4×
“Antimicrob Agents Chemother 35(8):1647–1650.”
InfluentialMaruri, F., Sterling, T. R., Kaiga, A. W., Blackman, A., van der Heijden, Y. F., Mayer, C., Cambau, E., & Aubry, A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr566 · Cited by 264 · cited 10×
“Amino acid substitutions within the QRDR can produce acquired resistance; however, of sequenced fluoroquinolone-resistant isolates, only 3% carry substitutions within the QRDR of GyrB compared with 64% within the QRDR of GyrA (11).”
BackgroundMethodInfluentialDawson, R., Diacon, A. H., Everitt, D., van Niekerk, C., Donald, P. R., Burger, D. A., Schall, R., Spigelman, M., Conradie, A., Eisenach, K., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62002-x · Cited by 241
Aubry, A., Pan, X.-S., Fisher, L. M., Jarlier, V., & Cambau, E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1281-1288.2004 · Cited by 240 · cited 2×
“5 μg/mL) are equally effective against Mtb, and that this correlates approximately with supercoiling inhibition, this trend did not correlate well with previously reported cleavage assays (32) or our own biochemical data (Fig.”
BackgroundResultWendorff, T. J., Schmidt, B. H., Heslop, P., Austin, C. A., & Berger, J. M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.07.014 · Cited by 240 · cited 1×
“2 C and D); this region has been seen in different conformational states in other type IIA topoisomerase structures (41, 42).”
BackgroundSelf-citationCURRENT PROGRESS IN STRUCTURE-BASED RATIONAL DRUG DESIGN MARKS A NEW MINDSET IN DRUG DISCOVERY
Lounnas, V., Ritschel, T., Kelder, J., McGuire, R., Bywater, R. P., & Foloppe, N. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201302011 · Cited by 213 · cited 1×
“Stacking energetics can also be difficult to modulate through structure-based drug design approaches (52, 53), which struggle with the accurate accounting of factors such as flexibility or the entropy of drug binding (54).”
BackgroundCoordination of water to magnesium cations
Bock, C. W., Kaufman, A., & Glusker, J. P. (1994) · Inorganic Chemistry · doi:10.1021/ic00081a007 · Cited by 190 · cited 1×
“observed with magnesium ions (45) and within crystal structures of individual quinolones (46)].”
BackgroundA novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases
Schmidt, B. H., Burgin, A. B., Deweese, J. E., Osheroff, N., & Berger, J. M. (2010) · Nature · doi:10.1038/nature08974 · Cited by 186 · cited 1×
“A single magnesium ion and several associated waters are present in each of the two active sites at the so-called “B” (noncatalytic) position (43), coordinated by Glu459, Asp532, and Asp534 of GyrB (Fig.”
BackgroundSelf-citationStructural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
Laponogov, I., Pan, X.-S., Veselkov, D. A., McAuley, K. E., Fisher, L. M., & Sanderson, M. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011338 · Cited by 178 · cited 4×
“Although numerous crystallographic studies have defined the primary binding site of fluoroquinolones against gyrase (and against topoisomerase IV, a gyrase paralog) (27–30), there has been debate as to whether fluoroquinolones use a magnesium ion to bridge their interaction with the enzyme (28, 29).”
BackgroundMethodInfluentialFluoroquinolone-Gyrase-DNA Complexes
Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L. M., Hiasa, H., Marks, K. R., Kerns, R. J., Berger, J. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529164 · Cited by 172
Self-citationAldred, K. J., McPherson, S. A., Turnbough, C. L., Kerns, R. J., & Osheroff, N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt124 · Cited by 171 · cited 1×
“DNA resealing is then assessed by the loss of linear product over time using agarose gel electrophoresis (37).”
MethodSelf-citationA national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009
Suda, K. J., Hicks, L. A., Roberts, R. M., Hunkler, R. J., & Danziger, L. H. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks445 · Cited by 162
Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase
Piton, J., Petrella, S., Delarue, M. H., André-Leroux, G., Jarlier, V., Aubry, A., & Mayer, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012245 · Cited by 161 · cited 1×
“Mtb is well known to have a low susceptibility to fluoroquinolones (34, 35).”
BackgroundZhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A. G., Ramaswamy, S. V., Domagala, J. M., Musser, J. M., & Drlica, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315708 · Cited by 148 · cited 1×
“One notable, watermediated magnesium-ion contact is with Asp94 of GyrA; this interaction likely accounts for why many substitutions at Asp94 lead to drug insensitivity in fluoroquinolone-resistant laboratory and clinical strain isolates (11, 47) (see also ref.”
BackgroundGuillemin, I., Jarlier, V., & Cambau, E. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.2084 · Cited by 145 · cited 1×
“For example, the WT minimal inhibitory concentration (MIC) for ciprofloxacin and levofloxacin is 20- and 140-fold higher, respectively, with Mtb than with Escherichia coli (31).”
ResultGrosset, J. H. E., Singer, T. G., & Bishai, W. R. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0277 · Cited by 131 · cited 2×
“Antimicrob Agents Chemother 53(9):3822–3831.”
BackgroundAldred, K. J., Blower, T. R., Kerns, R. J., Berger, J. M., & Osheroff, N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525055113 · Cited by 113
Self-citationAldred, K. J., McPherson, S. A., Wang, P., Kerns, R. J., Graves, D. E., Turnbough, C. L., & Osheroff, N. (2011) · Biochemistry · doi:10.1021/bi2013905 · Cited by 102 · cited 1×
“The stability assays were performed as follows, using a protocol adapted from previous examples (36, 63) (see also”
MethodSelf-citationBrigden, G., Hewison, C., & Varaine, F. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s68351 · Cited by 85
Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?
Migliori, G. B., Centis, R., D’Ambrosio, L., Spanevello, A., Borroni, E., Cirillo, D. M., & Sotgiu, G. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis128 · Cited by 81 · cited 1×
“5% of new TB cases; of these, 9% are classified as extensively drug-resistant (XDR)-TB (1), which is defined as MDR-TB with additional resistance to any fluoroquinolone and one injectable second-line drug (3).”
BackgroundAldred, K. J., Schwanz, H. A., Li, G., McPherson, S. A., Turnbough, C. L., Kerns, R. J., & Osheroff, N. (2013) · ACS Chemical Biology · doi:10.1021/cb400592n · Cited by 79 · cited 1×
“C8-Me-moxifloxacinwas synthesized as described previously (38).”
Self-citationCurrent Prospects for the Fluoroquinolones as First-Line Tuberculosis Therapy
Takiff, H. E., & Guerrero, E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00695-11 · Cited by 74 · cited 5×
“For example, ciprofloxacin is only marginally active, and its early use with Mtb was halted in favor of ofloxacin and levofloxacin (7).”
BackgroundResultInfluentialPan, X.-S., Gould, K. A., & Fisher, L. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-09 · Cited by 70
Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1
Lee, H., & Suh, J. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1709-3 · Cited by 67 · cited 2×
“These compounds have been used to restrict the development of XDR-TB from MDR-TB; however, emerging resistance threatens both first-line and second-line use (11).”
BackgroundMalik, M., Marks, K. R., MUSTAEV, A. A., Zhao, X., Chavda, K. D., Kerns, R. J., & Drlica, K. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00033-11 · Cited by 64
Self-citationBandele, O. J., & Osheroff, N. (2008) · Biochemistry · doi:10.1021/bi800981j · Cited by 60 · cited 1×
“Nevertheless, cleaved-complex stability correlates well with in vivo efficacy and is likely to relate to the killing of Mtb cells; this hypothesis is supported by previous data showing how complex stability is a determining factor for the cytotoxicity of topoisomerase poisons within eukaryotic cells (51).”
Aldred, K. J., Breland, E. J., Vlčková, V., Strub, M., Neuman, K. C., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi500682e · Cited by 59
Self-citationHuang, X., Zhang, A., Chen, D., Jia, Z., & Li, X. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.044 · Cited by 55 · cited 1×
“Much attention has already been paid to modifying C7 ring groups, with clear success (23, 49, 56); it seems likely that these improvements could be further capitalized upon by using longer linkers at the C7 position and allowing substituents to reach and contact side chains of amino acids such as Arg482, Thr500, or Gl…”
BackgroundUse of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones
German, N., Malik, M., Rosen, J. D., Drlica, K., & Kerns, R. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-08 · Cited by 49 · cited 1×
“Much attention has already been paid to modifying C7 ring groups, with clear success (23, 49, 56); it seems likely that these improvements could be further capitalized upon by using longer linkers at the C7 position and allowing substituents to reach and contact side chains of amino acids such as Arg482, Thr500, or Gl…”
BackgroundSelf-citationShortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?
Lanoix, J., Chaisson, R. E., & Nuermberger, E. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ911 · Cited by 45 · cited 1×
“Although recent clinical trials that have included fluoroquinolones as part of an alternative drug regimen have faltered (14), there are prospects for other nonfluoroquinolone molecules to make an impact on the treatment of MDR- and XDR-TB (15, 16).”
BackgroundMolina-Torres, C. A., Barba-Marines, A., Valles‐Guerra, O., Ocampo‐Candiani, J., Cavazos-Rocha, N., Pucci, M. J., Castro‐Garza, J., & Cabrera, L. V. (2014) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-13-13 · Cited by 42
Identification of the likely translational start of Mycobacterium tuberculosis GyrB
Karkare, S., Brown, A. C., Parish, T., & Maxwell, A. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-274 · Cited by 3 · cited 1×
“To begin to define how Mtb gyrase responds in vitro to different, clinically tested fluoroquinolones, we first purified fulllength Mtb GyrA and GyrB, using the new consensus 675-aa form of GyrB (11, 40).”
Method
Cited by
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Gibson, E. G., Bax, B., Chan, P. F., & Osheroff, N. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00315 · Cited by 178
“54-55 In contrast to fluoroquinolones, which bind in the DNA at the two four base-pair separated cleavage sites, 25, 30, 32-33 only a single molecule of gepotidacin binds in the S. aureus gyrase-DNA complex.”
BackgroundJiang, X., Wang, D., Wu, W., & Li, F. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114468 · Cited by 22
Jiang, X., Wang, D., Wu, W., & Li, F. (2023) · Environmental Science: Processes & Impacts · doi:10.1039/d2em00284a · Cited by 7
Metadata
- Authors
- Blower, T. R., Williamson, B. H., Kerns, R. J., & Berger, J. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-01-20
- Volume
- 113
- Issue
- 7
- Pages
- 1706-1713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2283132526
- Cited by
- 225
- References
- 61
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.